Abstract
The relationship between antibiotic stewardship and population levels of antibiotic resistance remains unclear. In order to better understand shifts in selective pressure due to stewardship, we use publicly available data to estimate the effect of changes in prescribing on exposures to frequently used antibiotics experienced by potentially pathogenic bacteria that are asymptomatically colonizing the microbiome. We quantify this impact under four hypothetical stewardship strategies. In one scenario, we estimate that elimination of all unnecessary outpatient antibiotic use could avert 6 to 48% (IQR: 17 to 31%) of exposures across pairwise combinations of sixteen common antibiotics and nine bacterial pathogens. All scenarios demonstrate that stewardship interventions, facilitated by changes in clinician behavior and improved diagnostics, have the opportunity to broadly reduce antibiotic exposures across a range of potential pathogens. Concurrent approaches, such as vaccines aiming to reduce infection incidence, are needed to further decrease exposures occurring in “necessary” contexts.
Competing Interest Statement
ML has received consulting income from Affinivax, Antigen Discovery, Merck, and Pfizer and research grants through Harvard School of Public Health from Pfizer and PATH. YHG has received consulting income from Merck and GlaxoSmithKline. The authors have no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This work was supported by Grant U54GM088558 (Models of Infectious Disease Agent Study, Center for Communicable Disease Dynamics) from the National Institute of General Medical Sciences, Grant R01AI132606 from the National Institute of Allergy and Infectious Diseases (to YHG), Grant CK000538-01 from the Centers for Disease Control and Prevention, and the Doris Duke Charitable Foundation. CT is supported by Grant T32AI007535 from the National Institute of Allergy and Infectious Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Centers for Disease Control and Prevention, Department of Health and Human Services, or the Doris Duke Charitable Foundation.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Not Applicable
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Not Applicable
Data Availability
Data is publicly available.
https://www.cdc.gov/nchs/ahcd/datasets_documentation_related.htm
